Jane M. Withka PhD

Jane Withka has over 25 years of experience in the pharmaceutical industry in support of macromolecular NMR and biophysical applications within a structural biology and biophysics group. She initiated fragment-based drug discovery (FBDD) at Pfizer and responsible for portfolio management and initiatives for fragment library design. She is a leadership role in the integration of alternative hit ID strategies including, FBDD, ASMS, and DEL technologies. Laboratory head of NMR and biophysics group within Structure and Molecular Sciences and responsible for the implementation and integration of lead identification, binding, and functional characterization and optimization methods into Pfizer’s discovery environment. Recently transitioned to director and collaboration lead to facilitate identification of new target classes and modalities for targeting with small molecules. She has received a Ph.D. in Biophysics from Wesleyan University and completed post-doctoral studies at Harvard Medical School. During the career, published over 41 research papers.